Depletion of recipient CD4+ but not CD8+ T lymphocytes prevents the development of cardiac allograft vasculopathy

被引:31
作者
Szeto, WY [1 ]
Krasinskas, AM [1 ]
Kreisel, D [1 ]
Krupnick, AS [1 ]
Popma, SH [1 ]
Rosengard, BR [1 ]
机构
[1] Hosp Univ Penn, Dept Surg, Div Cardiothorac Surg, Philadelphia, PA 19104 USA
关键词
D O I
10.1097/00007890-200204150-00019
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. We have described that chimeric rat hearts bearing recipient-type antigen-presenting cells (APCs) do not reject acutely, but develop cardiac allograft vasculopathy (CAV) in untreated recipients. This suggests that CAV is triggered either by CD8(+) direct allorecognition or by CD4(+) indirect allorecognition. To determine the allorecognition pathway responsible for CAV in this model, recipients of chimeric hearts underwent either CD8(+) or CD4(+) T cell depletion. Methods. Chimeric hearts were created via bone marrow transplantation in two fully major histocompatibility-mismatched rat strain combinations. DA recipients were thymectomized and treated with Ox8 and Ox38 murine monoclonal antibodies, which deplete CD8(+) and CD4(+) T cells, respectively. Chimeric PVG hearts bearing DA APCs, abbreviated PVG(DA), were heterotopically transplanted into recipients undergoing thymectomy alone or recipients undergoing thymectomy plus either CD4(+) or CD8(+) T cell depletion. Results. PVG(DA) allografts survived 100 days, but developed CAV in thymectomized recipients and in those permanently depleted of CD8(+) T cells. In contrast, chimeric hearts transplanted into permanently CD4(+) T cell-depleted recipients survived 100 days and demonstrated no evidence of CAV. Conclusions. In this specific strain combination, recipient CD8(+) T cells are neither necessary nor sufficient for the development of CAV, whereas recipient CD4(+) T cells are required for the development of CAV. These findings suggest that CAV is dependent on CD4(+) indirect allorecognition and that CD8(+) direct allorecognition stimulated by nonprofessional APCs plays a minor role.
引用
收藏
页码:1116 / 1122
页数:7
相关论文
共 32 条
  • [1] EXPERIMENTAL GRAFT ARTERIOSCLEROSIS .1. THE LEWIS-TO-F-344 ALLOGRAFT MODEL
    ADAMS, DH
    TILNEY, NL
    COLLINS, JJ
    KARNOVSKY, MJ
    [J]. TRANSPLANTATION, 1992, 53 (05) : 1115 - 1119
  • [2] Cardiac allograft vasculopathy is abrogated anti-CD8 monoclonal antibody therapy - Discussion
    Kirklin, JK
    Allan, JS
    Trinkle, JK
    Rosengard, BR
    [J]. ANNALS OF THORACIC SURGERY, 1997, 64 (04) : 1025 - 1025
  • [3] Heart allograft vascular disease - An obliterative vascular disease in transplanted hearts
    Andersen, HO
    [J]. ATHEROSCLEROSIS, 1999, 142 (02) : 243 - 263
  • [4] Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen
    Arima, T
    Lehmann, M
    Flye, MW
    [J]. TRANSPLANTATION, 1997, 63 (02) : 284 - 292
  • [5] Antigen processing and presentation in transplantation
    Auchincloss, H
    Sultan, H
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1996, 8 (05) : 681 - 687
  • [6] Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts
    Ciubotariu, R
    Liu, ZR
    Colovai, AI
    Ho, E
    Itescu, S
    Ravalli, S
    Hardy, MA
    Cortesini, R
    Rose, EA
    Suciu-Foca, N
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) : 398 - 405
  • [7] MRC OX-19 - A MONOCLONAL-ANTIBODY THAT LABELS RAT LYMPHOCYTES-T AND AUGMENTS INVITRO PROLIFERATIVE RESPONSES
    DALLMAN, MJ
    THOMAS, ML
    GREEN, JR
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1984, 14 (03) : 260 - 267
  • [8] Day JD, 1995, J HEART LUNG TRANSPL, V14, pS142
  • [9] IMPACT OF CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGEN EXPRESSION ON THE IMMUNOGENIC POTENTIAL OF ISOLATED RAT VASCULAR ENDOTHELIAL-CELLS
    FERRY, B
    HALTTUNEN, J
    LESZCZYNSKI, D
    SCHELLEKENS, H
    VANDERMEIDE, PH
    HAYRY, P
    [J]. TRANSPLANTATION, 1987, 44 (04) : 499 - 503
  • [10] FLAVIN T, 1990, J HEART TRANSPLANT, V9, P482